Nutrition supplement maker Glanbia announced plans to sell its underperforming U.S. weight management brand SlimFast on ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Hyderabad: Organisation for Rare Diseases India (ORDI), supported by Novo Nordisk India, has hosted the 10th edition of ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...